Evar Trial Participants

The Lancet · 2005

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Evar Trial Participants trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Moneta

Papers from Evar Trial Participants's perspective

Ordered by how strongly the researchers Evar Trial Participants trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). (Journal of Vascular Surgery)
  2. Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000 (Circulation)
  3. Radiation Dose Associated with Common Computed Tomography Examinations and the Associated Lifetime Attributable Risk of Cancer (Archives of Internal Medicine)
  4. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
  5. Diabetic Foot Ulcers and Their Recurrence. (New England Journal of Medicine)
  6. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. (Journal of the American College of Cardiology)
  7. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). (Journal of Vascular Surgery)
  8. Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results (Circulation. Cardiovascular Interventions)
  9. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3… (The Lancet)
  10. Epidemiology of peripheral artery disease. (Circulation Research)

Their papers